Thrivent Financial for Lutherans Buys 152,603 Shares of Bruker Corporation $BRKR

Thrivent Financial for Lutherans increased its stake in shares of Bruker Corporation (NASDAQ:BRKR) by 561.3% during the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 179,792 shares of the medical research company’s stock after acquiring an additional 152,603 shares during the quarter. Thrivent Financial for Lutherans’ holdings in Bruker were worth $8,470,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other institutional investors and hedge funds have also bought and sold shares of the company. Allworth Financial LP grew its position in Bruker by 40.6% during the 3rd quarter. Allworth Financial LP now owns 890 shares of the medical research company’s stock worth $29,000 after acquiring an additional 257 shares during the last quarter. CWM LLC lifted its holdings in Bruker by 49.8% in the 4th quarter. CWM LLC now owns 1,631 shares of the medical research company’s stock worth $77,000 after buying an additional 542 shares during the period. EverSource Wealth Advisors LLC lifted its holdings in Bruker by 51.5% in the 2nd quarter. EverSource Wealth Advisors LLC now owns 2,770 shares of the medical research company’s stock worth $114,000 after buying an additional 942 shares during the period. Jones Financial Companies Lllp lifted its holdings in Bruker by 79.7% in the 3rd quarter. Jones Financial Companies Lllp now owns 2,773 shares of the medical research company’s stock worth $86,000 after buying an additional 1,230 shares during the period. Finally, Tower Research Capital LLC TRC lifted its holdings in Bruker by 56.0% in the 2nd quarter. Tower Research Capital LLC TRC now owns 4,172 shares of the medical research company’s stock worth $172,000 after buying an additional 1,497 shares during the period. 79.52% of the stock is currently owned by institutional investors.

Wall Street Analysts Forecast Growth

Several equities research analysts have weighed in on the company. Wall Street Zen upgraded Bruker from a “hold” rating to a “buy” rating in a report on Saturday, May 9th. UBS Group increased their price objective on Bruker from $40.00 to $45.00 and gave the stock a “neutral” rating in a report on Thursday, May 7th. The Goldman Sachs Group dropped their price objective on Bruker from $40.00 to $35.00 and set a “sell” rating for the company in a report on Friday, February 13th. Citigroup increased their price objective on Bruker from $40.00 to $44.00 and gave the stock a “neutral” rating in a report on Thursday, May 7th. Finally, Jefferies Financial Group set a $50.00 price objective on Bruker in a report on Thursday, February 12th. One research analyst has rated the stock with a Strong Buy rating, seven have assigned a Buy rating, five have given a Hold rating and two have issued a Sell rating to the company. Based on data from MarketBeat.com, the company currently has a consensus rating of “Hold” and an average price target of $50.54.

Bruker Trading Down 0.4%

BRKR opened at $42.59 on Wednesday. The stock has a market cap of $6.48 billion, a PE ratio of -177.46, a PEG ratio of 2.56 and a beta of 1.12. The company has a quick ratio of 0.72, a current ratio of 1.55 and a debt-to-equity ratio of 0.67. The business has a 50 day moving average of $37.95 and a 200-day moving average of $42.33. Bruker Corporation has a 52 week low of $28.53 and a 52 week high of $56.22.

Bruker (NASDAQ:BRKR) last released its earnings results on Wednesday, May 6th. The medical research company reported $0.31 EPS for the quarter, beating analysts’ consensus estimates of $0.23 by $0.08. The company had revenue of $823.40 million during the quarter, compared to analysts’ expectations of $795.62 million. Bruker had a positive return on equity of 11.60% and a negative net margin of 0.65%.The firm’s revenue for the quarter was up 2.7% compared to the same quarter last year. During the same quarter last year, the business posted $0.47 EPS. Bruker has set its FY 2026 guidance at 2.100-2.150 EPS. Equities research analysts predict that Bruker Corporation will post 2.12 earnings per share for the current fiscal year.

Bruker Dividend Announcement

The company also recently announced a quarterly dividend, which will be paid on Tuesday, July 7th. Stockholders of record on Monday, June 22nd will be paid a $0.05 dividend. This represents a $0.20 dividend on an annualized basis and a dividend yield of 0.5%. The ex-dividend date is Monday, June 22nd. Bruker’s dividend payout ratio (DPR) is presently -83.33%.

Insider Activity at Bruker

In other news, VP Mark Munch sold 2,000 shares of the firm’s stock in a transaction that occurred on Wednesday, April 15th. The stock was sold at an average price of $39.90, for a total value of $79,800.00. Following the completion of the transaction, the vice president owned 128,443 shares in the company, valued at $5,124,875.70. This trade represents a 1.53% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. 27.20% of the stock is currently owned by insiders.

Bruker Profile

Bruker Corporation, founded in 1960 by physicist Günther Laukien and headquartered in Billerica, Massachusetts, is a leading developer and manufacturer of high-performance scientific instruments and analytical solutions. The company designs systems that enable molecular and materials research across academic, governmental, and industrial laboratories.

Bruker’s product portfolio encompasses nuclear magnetic resonance (NMR) spectrometers for molecular structure and dynamics studies, mass spectrometry platforms for proteomics and metabolomics, X-ray diffraction and scattering instruments for crystallography and materials characterization, atomic force and scanning probe microscopes for nanoscale surface analysis, as well as preclinical imaging systems such as micro-CT and MRI scanners.

In addition to hardware, Bruker provides software suites, applications support, training services, and long-term maintenance agreements to ensure optimal instrument performance.